• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

腹膜透析患者的心血管死亡率:矿物质代谢紊乱的影响。

Cardiovascular mortality in peritoneal dialysis: the impact of mineral disorders.

机构信息

Universidade de São Paulo, Laboratório de Fisiopatologia Renal, São Paulo, SP, Brasil.

Pontifícia Universidade Católica do Paraná, Faculdade de Medicina, Curitiba, PR, Brasil.

出版信息

J Bras Nefrol. 2021 Apr-Jun;43(2):182-190. doi: 10.1590/2175-8239-JBN-2020-0040.

DOI:10.1590/2175-8239-JBN-2020-0040
PMID:33576763
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8257281/
Abstract

INTRODUCTION

Mineral and bone disorders (MBD) are associated with higher mortality in dialysis patients. The main guidelines related to the subject, Kidney Disease Outcomes Quality Initiative (KDOQI) and Kidney Disease: Improving Global Outcomes (KDIGO), were elaborated based on published information from hemodialysis participants. The aim of our study was to evaluate the impact of calcium (Ca), phosphorus (P), and parathyroid hormone (PTH) (according to guideline ranges from KDOQI and KDIGO) on the cardiovascular mortality of peritoneal dialysis (PD) patients.

METHODS

We used the BRAZPDII database, an observational multi-centric prospective study, which assessed participants on PD between December 2004 and January 2011. Amongst 9,905 participants included in this database, we analyzed 4424 participants who were on PD for at least 6 months. The appropriate confounding variables were entered into the model. Serum levels of Ca, P, and PTH were the variables of interest for the purposes of the current study.

RESULTS

We found a significant association between high P serum levels, categorized by KDOQI and KDIGO (P above 5.5 mg/dL), and cardiovascular survival (p < 0.01). Likewise, a compelling association was found between lower levels of PTH, categorized by guidelines (KDOQI and KDIGO - PTH less than 150 pg/mL, p < 0.01), and cardiovascular survival.

CONCLUSION

In conclusion, levels of P above and PTH below the values proposed by KDOQI and KDIGO were associated with cardiovascular mortality in PD patients.

摘要

简介

矿物质和骨代谢紊乱(MBD)与透析患者的死亡率升高有关。与该主题相关的主要指南,肾脏病预后质量倡议(KDOQI)和肾脏病:改善全球结果(KDIGO),是基于血液透析参与者的已发表信息制定的。我们的研究目的是评估钙(Ca),磷(P)和甲状旁腺激素(PTH)(根据 KDOQI 和 KDIGO 的指南范围)对腹膜透析(PD)患者心血管死亡率的影响。

方法

我们使用了 BRAZPDII 数据库,这是一项观察性多中心前瞻性研究,评估了 2004 年 12 月至 2011 年 1 月之间接受 PD 的参与者。在该数据库中,共纳入了 9905 名参与者,其中 4424 名参与者接受 PD 治疗时间至少为 6 个月。适当的混杂变量被纳入模型。本研究目的是分析血清 Ca,P 和 PTH 水平。

结果

我们发现高磷血清水平(根据 KDOQI 和 KDIGO 分类,P 高于 5.5mg/dL)与心血管生存率之间存在显著相关性(p<0.01)。同样,我们还发现 PTH 水平较低(根据指南分类,KDOQI 和 KDIGO - PTH 低于 150pg/mL)与心血管生存率之间存在强烈的相关性(p<0.01)。

结论

总之,KDOQI 和 KDIGO 提出的 P 和 PTH 值以上和以下水平与 PD 患者的心血管死亡率相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d65b/8257281/a388b4ff9cc9/2175-8239-jbn-2020-0040-gf04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d65b/8257281/6a607fd01fe5/2175-8239-jbn-2020-0040-gf01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d65b/8257281/cc9a6b77c009/2175-8239-jbn-2020-0040-gf02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d65b/8257281/5203817d668a/2175-8239-jbn-2020-0040-gf03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d65b/8257281/a388b4ff9cc9/2175-8239-jbn-2020-0040-gf04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d65b/8257281/6a607fd01fe5/2175-8239-jbn-2020-0040-gf01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d65b/8257281/cc9a6b77c009/2175-8239-jbn-2020-0040-gf02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d65b/8257281/5203817d668a/2175-8239-jbn-2020-0040-gf03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d65b/8257281/a388b4ff9cc9/2175-8239-jbn-2020-0040-gf04.jpg

相似文献

1
Cardiovascular mortality in peritoneal dialysis: the impact of mineral disorders.腹膜透析患者的心血管死亡率:矿物质代谢紊乱的影响。
J Bras Nefrol. 2021 Apr-Jun;43(2):182-190. doi: 10.1590/2175-8239-JBN-2020-0040.
2
International variations in serum PTH and calcium levels and their mortality associations in peritoneal dialysis patients: Results from PDOPPS.腹膜透析患者血清 PTH 和钙水平的国际差异及其与死亡率的关系:PDOPPS 研究结果。
Perit Dial Int. 2024 Jul;44(4):275-286. doi: 10.1177/08968608241235516. Epub 2024 Mar 19.
3
Prevalence of chronic kidney disease-mineral and bone disorder in incident peritoneal dialysis patients and its association with short-term outcomes.新发腹膜透析患者慢性肾脏病-矿物质和骨异常的患病率及其与短期预后的关系。
Singapore Med J. 2016 Nov;57(11):603-609. doi: 10.11622/smedj.2015195. Epub 2015 Dec 29.
4
Association between Hemodialysis Patient Outcomes and Compliance with KDOQI and KDIGO Targets for Mineral and Bone Metabolism.血液透析患者结局与遵循KDOQI和KDIGO矿物质及骨代谢目标之间的关联
Nephron. 2016;132(3):168-74. doi: 10.1159/000443848. Epub 2016 Feb 26.
5
High prevalence of biochemical disturbances of chronic kidney disease - mineral and bone disorders (CKD-MBD) in a nation-wide peritoneal dialysis cohort: are guideline goals too hard to achieve?在全国性腹膜透析队列中,慢性肾脏病-矿物质和骨异常(CKD-MBD)的生化紊乱患病率很高:指南目标是否太难实现?
J Bras Nefrol. 2021 Apr-Jun;43(2):173-181. doi: 10.1590/2175-8239-JBN-2020-0147.
6
KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).KDIGO 美国评论:2017 年 KDIGO 慢性肾脏病-矿物质和骨异常(CKD-MBD)诊治临床实践指南更新。
Am J Kidney Dis. 2017 Dec;70(6):737-751. doi: 10.1053/j.ajkd.2017.07.019. Epub 2017 Sep 21.
7
Comparative Effectiveness of Dialysis Modality on Laboratory Parameters of Mineral Metabolism.透析模式对矿物质代谢实验室参数的比较效果。
Am J Nephrol. 2022;53(2-3):157-168. doi: 10.1159/000521508. Epub 2022 Feb 28.
8
Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).不同血清钙、磷和甲状旁腺激素水平的透析患者的死亡风险:透析结局和实践模式研究(DOPPS)
Am J Kidney Dis. 2008 Sep;52(3):519-30. doi: 10.1053/j.ajkd.2008.03.020. Epub 2008 Jun 2.
9
The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients.《慢性肾脏病骨代谢与疾病的肾脏病预后质量倡议(K/DOQI)指南》:与透析患者死亡率的关联
Am J Kidney Dis. 2005 Nov;46(5):925-32. doi: 10.1053/j.ajkd.2005.08.013.
10
Gaps between Global Guidelines and Local Practices in CKD-MBD.慢性肾脏病-矿物质和骨异常全球指南与地方实践之间的差距
Electrolyte Blood Press. 2014 Dec;12(2):35-40. doi: 10.5049/EBP.2014.12.2.35. Epub 2014 Dec 31.

引用本文的文献

1
Serum zinc levels in hemodialysis and peritoneal dialysis patients: A retrospective observational study.血液透析和腹膜透析患者的血清锌水平:一项回顾性观察研究。
J Res Med Sci. 2024 Mar 29;29:13. doi: 10.4103/jrms.jrms_167_23. eCollection 2024.
2
Longer serum phosphorus time in range associated with lower mortality risk among peritoneal dialysis patients: a multicenter retrospective cohort study.血清磷时间在范围内与腹膜透析患者的死亡风险降低相关:一项多中心回顾性队列研究。
BMC Nephrol. 2024 Mar 29;25(1):117. doi: 10.1186/s12882-023-03395-9.
3
BMD in peritoneal dialysis: what BRAZPD can help us understand?

本文引用的文献

1
Peritoneal dialysis has optimal intradialytic hemodynamics and preserves residual renal function: Why isn't it better than hemodialysis?腹膜透析具有最佳的透析内血流动力学,并能保留残余肾功能:为什么它不比血液透析更好?
Semin Dial. 2019 Jan;32(1):3-8. doi: 10.1111/sdi.12752. Epub 2018 Oct 23.
2
Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder: Synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update.慢性肾脏病-矿物质和骨异常的诊断、评估、预防和治疗:肾脏病改善全球结局组织 2017 年临床实践指南更新概要。
Ann Intern Med. 2018 Mar 20;168(6):422-430. doi: 10.7326/M17-2640. Epub 2018 Feb 20.
3
腹膜透析中的骨密度:巴西腹膜透析登记研究能帮助我们了解什么?
J Bras Nefrol. 2021 Apr-Jun;43(2):150-151. doi: 10.1590/2175-8239-JBN-2021-E003.
Roles of Serum Calcium, Phosphorus, PTH and ALP on Mortality in Peritoneal Dialysis Patients: A Nationwide, Population-based Longitudinal Study Using TWRDS 2005-2012.
血清钙、磷、PTH 和 ALP 对腹膜透析患者死亡率的作用:使用 TWRDS 2005-2012 进行的全国性、基于人群的纵向研究。
Sci Rep. 2017 Feb 24;7(1):33. doi: 10.1038/s41598-017-00080-4.
4
Vascular calcification in CKD-MBD: Roles for phosphate, FGF23, and Klotho.慢性肾脏病-矿物质和骨异常中的血管钙化:磷酸盐、成纤维细胞生长因子23及α-klotho蛋白的作用
Bone. 2017 Jul;100:87-93. doi: 10.1016/j.bone.2016.11.012. Epub 2016 Nov 12.
5
Risk of fracture in adults on renal replacement therapy: a Danish national cohort study.接受肾脏替代治疗的成年人骨折风险:一项丹麦全国队列研究。
Nephrol Dial Transplant. 2016 Oct;31(10):1654-62. doi: 10.1093/ndt/gfw073. Epub 2016 Apr 19.
6
United States Renal Data System public health surveillance of chronic kidney disease and end-stage renal disease.美国肾脏数据系统对慢性肾脏病和终末期肾病的公共卫生监测。
Kidney Int Suppl (2011). 2015 Jun;5(1):2-7. doi: 10.1038/kisup.2015.2.
7
Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study.矿物质和骨代谢标志物的改善与血液透析患者的生存改善相关:COSMOS 研究。
Nephrol Dial Transplant. 2015 Sep;30(9):1542-51. doi: 10.1093/ndt/gfv099. Epub 2015 Apr 28.
8
Characterization of the BRAZPD II cohort and description of trends in peritoneal dialysis outcome across time periods.BRAZPD II队列的特征及不同时间段腹膜透析结局趋势的描述。
Perit Dial Int. 2014 Nov-Dec;34(7):714-23. doi: 10.3747/pdi.2013.00282. Epub 2014 Sep 2.
9
Novel predictors of peritonitis-related outcomes in the BRAZPD cohort.BRAZPD队列中腹膜炎相关结局的新型预测指标。
Perit Dial Int. 2014 Mar-Apr;34(2):179-87. doi: 10.3747/pdi.2012.00333. Epub 2014 Jan 2.
10
Relationship between alkaline phosphatase and all-cause mortality in peritoneal dialysis patients.腹膜透析患者碱性磷酸酶与全因死亡率的关系。
Adv Perit Dial. 2013;29:61-3.